Dear MG Community,

You hopefully received recent communication from the Myasthenia Alliance Australia (MAA) about the current opportunity to make a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) for a new treatment called Ravulizumab.

We mentioned that alongside your individual submission (if you’d like to make one), the MAA is making a submission as the national organisation representing and advocating for MG patients in Australia. We aim to ensure that our submission is supported with evidence including direct feedback and information from patients.

So, to help us with this submission on your behalf, we’d like to ask 5 quick questions via an online survey. It will take just 2 minutes to complete and will be open until Wednesday 10 January 2024.  

Please click here to access the survey: https://www.surveymonkey.com/r/J3DGV3M 

Thank you for your contribution to this important work.

Kind regards,
The MAA Board